Breakpoint Therapeutics

Germany
Hespe, Lower Saxony, Germany, 22419

Company profile

Breakpoint Therapeutics company profile

Breakpoint Therapeutics is a company that discover and develop new anti-cancer drugs. By targeting the DNA damage response (“DDR”) in cancer cells, Breakpoint Therapeutics aims to advance to clinical development first-in-class oncology drugs that interfere with DNA repair and replication stress tolerance pathways. Their mission is to develop drugs that succeed and complement PARP inhibitors and facilitate the cure of therapy resistant cancers.

Business identity

Contact email
[email protected]
Phone number
+49 40 56081 180
Operating status
Active
Company type
For Profit
Employee range
1-10 employees
Revenue range
$0-$1M
Founded
2019-01-01, Year

Headquarters

Postal code
22419
Country code
DE
Continent
Europe

Capital profile

Funding and company signals

Funding rounds
1
Total equity funding
$33.6M
Last funding
Series Unknown / $33.6M / 2019-07-09
Last equity funding
Series Unknown / $33.6M
Investors
3
Lead investors
1
Founders
1
Articles
6

Founders and investors

Founders

Jonathan Hollick

Lead investors

Medicxi

Investors

EvotecMedicxiTaiho Ventures